Form 8-K - Current report:
SEC Accession No. 0001104659-23-118751
Filing Date
2023-11-15
Accepted
2023-11-15 17:03:27
Documents
13
Period of Report
2023-11-14
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330847d1_8k.htm   iXBRL 8-K 36161
  Complete submission text file 0001104659-23-118751.txt   257032

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cycc-20231114.xsd EX-101.SCH 3260
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cycc-20231114_def.xml EX-101.DEF 26928
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cycc-20231114_lab.xml EX-101.LAB 36551
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cycc-20231114_pre.xml EX-101.PRE 25552
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2330847d1_8k_htm.xml XML 4945
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 231411401
SIC: 2834 Pharmaceutical Preparations